CA2441702A1 - Proteines secretees par l'homme - Google Patents
Proteines secretees par l'homme Download PDFInfo
- Publication number
- CA2441702A1 CA2441702A1 CA002441702A CA2441702A CA2441702A1 CA 2441702 A1 CA2441702 A1 CA 2441702A1 CA 002441702 A CA002441702 A CA 002441702A CA 2441702 A CA2441702 A CA 2441702A CA 2441702 A1 CA2441702 A1 CA 2441702A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- referenced
- fragment
- cdna clone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title description 95
- 102000004169 proteins and genes Human genes 0.000 title description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 274
- 229920001184 polypeptide Polymers 0.000 claims abstract description 270
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 269
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 145
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 145
- 239000002157 polynucleotide Substances 0.000 claims abstract description 144
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 50
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 43
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 41
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 41
- 239000013598 vector Substances 0.000 claims abstract description 41
- 201000011510 cancer Diseases 0.000 claims abstract description 29
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 18
- 239000000556 agonist Substances 0.000 claims abstract description 11
- 239000005557 antagonist Substances 0.000 claims abstract description 11
- 239000002299 complementary DNA Substances 0.000 claims description 128
- 239000012634 fragment Substances 0.000 claims description 101
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 83
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
- 230000004071 biological effect Effects 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000007423 decrease Effects 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 28
- 239000000203 mixture Substances 0.000 abstract description 12
- 238000012216 screening Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000010189 synthetic method Methods 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000010188 recombinant method Methods 0.000 abstract description 3
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 72
- 230000000875 corresponding effect Effects 0.000 description 50
- 201000010099 disease Diseases 0.000 description 48
- 125000003729 nucleotide group Chemical group 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 44
- 239000002773 nucleotide Substances 0.000 description 43
- 239000000523 sample Substances 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 32
- 208000035475 disorder Diseases 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 25
- 108700026244 Open Reading Frames Proteins 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 238000005516 engineering process Methods 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000002759 chromosomal effect Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 10
- 102100025409 Orofacial cleft 1 candidate gene 1 protein Human genes 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 101000941356 Nostoc ellipsosporum Cyanovirin-N Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 108091005461 Nucleic proteins Proteins 0.000 description 5
- 238000001815 biotherapy Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002969 morbid Effects 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- SSURCGGGQUWIHH-UHFFFAOYSA-N NNON Chemical compound NNON SSURCGGGQUWIHH-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000001723 extracellular space Anatomy 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 3
- -1 allelic variants Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 3
- 229960004583 pranlukast Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000282461 Canis lupus Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- MFHHXXRRFHXQJZ-UHFFFAOYSA-N NONON Chemical compound NONON MFHHXXRRFHXQJZ-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 238000000670 ligand binding assay Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- PVFZKRMYBKEXBN-UHFFFAOYSA-N piperidine;piperidine-1-carbodithioic acid Chemical compound C1CCNCC1.SC(=S)N1CCCCC1 PVFZKRMYBKEXBN-UHFFFAOYSA-N 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101000941450 Lasioglossum laticeps Lasioglossin-1 Proteins 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101100429014 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) xan-1 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- RQBWISLGURQVFU-UHFFFAOYSA-N ONONONONO Chemical compound ONONONONO RQBWISLGURQVFU-UHFFFAOYSA-N 0.000 description 1
- KUGRPPRAQNPSQD-UHFFFAOYSA-N OOOOO Chemical compound OOOOO KUGRPPRAQNPSQD-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 101100029763 Rattus norvegicus Inpp5j gene Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000012233 TRIzol extraction Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003312 immunocapture Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108010087204 oncoimmunin-M Proteins 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108010039177 polyphenylalanine Proteins 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000002416 scanning tunnelling spectroscopy Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011317 telomere syndrome Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne des polypeptides sécrétés par l'homme et des molécules d'acides nucléiques isolées codant lesdits polypeptides, servant au diagnostic et au traitement du cancer et d'autres maladies et troubles hyperproliférants. L'invention concerne également des anticorps liant ces polypeptides, des vecteurs, des cellules hôtes, et des procédés de recombinaison et de synthèse destinés à la fabrication desdits polynucléotides, polypeptides et/ou anticorps. L'invention concerne également des procédés de criblage destinés à identifier des agonistes et des antagonistes des polynucléotides et polypeptides selon l'invention. L'invention concerne également des procédés et des compostions destinés à inhiber ou promouvoir la production et la fonction des polypeptides selon l'invention.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27734001P | 2001-03-21 | 2001-03-21 | |
| US60/277,340 | 2001-03-21 | ||
| US30617101P | 2001-07-19 | 2001-07-19 | |
| US60/306,171 | 2001-07-19 | ||
| US33128701P | 2001-11-13 | 2001-11-13 | |
| US60/331,287 | 2001-11-13 | ||
| PCT/US2002/008123 WO2002102993A2 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees par l'homme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2441702A1 true CA2441702A1 (fr) | 2002-12-27 |
Family
ID=27402891
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002441702A Abandoned CA2441702A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees par l'homme |
| CA002441832A Abandoned CA2441832A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
| CA002441840A Abandoned CA2441840A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
| CA002441397A Abandoned CA2441397A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines humaines secretees |
| CA002441416A Abandoned CA2441416A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines humaines secretees |
| CA002441417A Abandoned CA2441417A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees par les humains |
| CA002441755A Abandoned CA2441755A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002441832A Abandoned CA2441832A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
| CA002441840A Abandoned CA2441840A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
| CA002441397A Abandoned CA2441397A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines humaines secretees |
| CA002441416A Abandoned CA2441416A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines humaines secretees |
| CA002441417A Abandoned CA2441417A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees par les humains |
| CA002441755A Abandoned CA2441755A1 (fr) | 2001-03-21 | 2002-03-19 | Proteines secretees humaines |
Country Status (4)
| Country | Link |
|---|---|
| EP (7) | EP1423134A2 (fr) |
| AU (6) | AU2002332391A1 (fr) |
| CA (7) | CA2441702A1 (fr) |
| WO (7) | WO2003038063A2 (fr) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7196164B2 (en) | 1997-07-08 | 2007-03-27 | Human Genome Sciences, Inc. | Secreted protein HHTLF25 |
| JP2002513295A (ja) | 1997-07-08 | 2002-05-08 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | １２３種類のヒト分泌タンパク質 |
| US20040141975A1 (en) | 1998-06-01 | 2004-07-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6329503B1 (en) | 1998-06-01 | 2001-12-11 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US20060052321A1 (en) | 2002-04-05 | 2006-03-09 | Raitano Arthur B | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| EP1141027A1 (fr) | 1999-01-15 | 2001-10-10 | Biogen, Inc. | Antagonistes de la proteine tweak et du recepteur de tweak, et leur utilisation pour traiter des affections immunitaires |
| US20060073150A1 (en) | 2001-09-06 | 2006-04-06 | Mary Faris | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| US7291719B2 (en) | 2000-07-25 | 2007-11-06 | Genentech, Inc. | PRO4332 antibodies |
| EP1666490A3 (fr) * | 2000-07-25 | 2006-11-02 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci |
| JP2004528823A (ja) | 2000-10-31 | 2004-09-24 | ディアデクサス インコーポレーテッド | 大腸特異的遺伝子およびタンパク質に関する組成物および方法 |
| US20020111302A1 (en) * | 2000-11-30 | 2002-08-15 | Y. Tom Tang | Novel nucleic acids and polypeptides |
| WO2002083921A2 (fr) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers |
| US7250495B2 (en) | 2001-06-20 | 2007-07-31 | Genentech, Inc. | PRO20044 polypeptides |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| EP1439235A4 (fr) | 2001-10-12 | 2006-01-18 | Astellas Pharma Inc | Methode de criblage d'inhibiteur de mort cellulaire |
| AU2003224950B2 (en) | 2002-04-09 | 2006-09-14 | Biogen Ma Inc. | Methods for treating tweak-related conditions |
| AU2003900747A0 (en) * | 2003-02-18 | 2003-03-06 | Garvan Institute Of Medical Research | Diagnosis and treatment of pancreatic cancer |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| WO2005019258A2 (fr) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions et methodes de traitement de maladies relatives au systeme immunitaire |
| US7687233B2 (en) | 2003-09-23 | 2010-03-30 | The University Of North Carolina At Chapel Hill | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage |
| ES2379764T3 (es) * | 2003-10-14 | 2012-05-03 | Baxter International Inc. | Polipéptido VKORC1 de reciclaje de la vitamina K-epóxido, una diana terapéutica de la curamina y sus derivados |
| EP1714154A2 (fr) * | 2004-02-03 | 2006-10-25 | Bayer HealthCare AG | Agents diagnostiques et therapeutiques pour des maladies associes a la glutamate carboxypeptidase (pgcp) plasmatique |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| MXPA06012187A (es) | 2004-04-22 | 2007-03-28 | Agensys Inc | Anticuerpos y moleculas derivadas de estas que se enlazan a las proteinas steap-1. |
| US8759305B2 (en) * | 2004-09-01 | 2014-06-24 | Dynavax Technologies Corporation | Methods and compositions for inhibition of innate immune responses and autoimmunity |
| JP2008512099A (ja) * | 2004-09-07 | 2008-04-24 | テレソン インスティテュート フォー チャイルド ヘルス リサーチ | アレルギー性疾患の処置または予防のための物質 |
| WO2006026808A1 (fr) * | 2004-09-07 | 2006-03-16 | Telethon Institute For Child Health Research | Methode de diagnostic et/ou de prediction du developpement d'une affection allergique |
| US20090124993A1 (en) | 2005-02-17 | 2009-05-14 | Burkly Linda C | Treating neurological disorders |
| US9617523B2 (en) | 2005-02-28 | 2017-04-11 | Baxalta GmbH | Nucleic acids encoding vitamin K expoxide reductase subunit 1 and vitamin K dependent protein expression and methods of using same |
| AU2005329450A1 (en) | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active Vitamin K-dependent proteins |
| JP5339901B2 (ja) | 2005-05-10 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 炎症傷害の処置および評価 |
| WO2006138219A2 (fr) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Procedes d'evaluation de patients |
| GB2445882B (en) * | 2005-09-01 | 2011-02-23 | Florey Howard Inst | Prophylactic and therapeutic agents and compositions and uses therefor and methods for determining the presence or severity of neuronal damage |
| GB0521488D0 (en) * | 2005-10-21 | 2005-11-30 | Ares Trading Sa | Integral membrane protein |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| NZ576132A (en) | 2006-10-27 | 2012-04-27 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
| WO2008063382A2 (fr) | 2006-11-07 | 2008-05-29 | Merck & Co., Inc. | Antagonistes de pcsk9 |
| US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| WO2008118386A2 (fr) * | 2007-03-27 | 2008-10-02 | Merck & Co., Inc. | Procédé de détection de pcsk9 sécrétée, autogénérée |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| EP2209896B1 (fr) | 2007-10-26 | 2017-03-01 | Dynavax Technologies Corporation | Procédés et compositions pour inhiber les réponses immunitaires et l'auto-immunité |
| US8017573B2 (en) * | 2007-11-30 | 2011-09-13 | Siemens Healthcare Diagnostics Inc. | Adiponectin receptor fragments and methods of use |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| US8748115B2 (en) | 2008-12-12 | 2014-06-10 | Merck Sharp & Dohme Corp. | PCSK9 immunoassay |
| AU2010313324A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX213 and AX132 PCSK9 antagonists and variants |
| US8802827B2 (en) | 2009-10-30 | 2014-08-12 | Merck Sharp & Dohme Corp. | AX1 PCSK9 antagonists |
| CN103153346A (zh) | 2010-06-16 | 2013-06-12 | 戴纳瓦克斯技术公司 | 使用tlr7和/或tlr9抑制剂的治疗方法 |
| JP6012605B2 (ja) | 2010-09-22 | 2016-10-25 | アリオス バイオファーマ インク． | 置換されたヌクレオチドアナログ |
| US9631002B2 (en) | 2010-12-21 | 2017-04-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin K-dependent proteins |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| WO2013096680A1 (fr) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Analogues de nucléotide phosphorothioate substitués |
| EP2828277A1 (fr) | 2012-03-21 | 2015-01-28 | Vertex Pharmaceuticals Incorporated | Formes solides d'un promédicament nucléotidique thiophosphoramidate |
| WO2013142157A1 (fr) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Combinaisons pharmaceutiques comprenant un analogue thionucléotidique |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US9682218B2 (en) | 2013-12-23 | 2017-06-20 | Carefusion 2200, Inc. | Pleurodesis device and method |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| EP3534947A1 (fr) | 2016-11-03 | 2019-09-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
| WO2018119354A1 (fr) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Édition génique de pcsk9 |
| BR112019018767A2 (pt) | 2017-04-03 | 2020-05-05 | Hoffmann La Roche | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção |
| WO2018237213A1 (fr) | 2017-06-22 | 2018-12-27 | The Procter & Gamble Company | Films comprenant une couche hydrosoluble et un revêtement inorganique déposé en phase vapeur |
| WO2018237212A1 (fr) | 2017-06-22 | 2018-12-27 | The Procter & Gamble Company | Films comprenant une couche hydrosoluble et un revêtement organique déposé en phase vapeur |
| BR112022020428A2 (pt) | 2020-04-09 | 2023-03-07 | Verve Therapeutics Inc | Edição base do angptl3 e métodos de uso do mesmo para tratamento de doenças |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100236393B1 (ko) * | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| WO2002026931A2 (fr) * | 2000-09-25 | 2002-04-04 | Human Genome Sciences, Inc. | 71 proteines humaines secretees |
| US5858716A (en) * | 1997-05-30 | 1999-01-12 | Smithkline Beecham Corporation | H2CAA71 polynucleotides |
| JP2002520050A (ja) * | 1998-07-15 | 2002-07-09 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ７１個のヒト分泌タンパク質 |
-
2002
- 2002-03-19 CA CA002441702A patent/CA2441702A1/fr not_active Abandoned
- 2002-03-19 EP EP02780789A patent/EP1423134A2/fr not_active Withdrawn
- 2002-03-19 AU AU2002332391A patent/AU2002332391A1/en not_active Abandoned
- 2002-03-19 CA CA002441832A patent/CA2441832A1/fr not_active Abandoned
- 2002-03-19 CA CA002441840A patent/CA2441840A1/fr not_active Abandoned
- 2002-03-19 WO PCT/US2002/008277 patent/WO2003038063A2/fr not_active Ceased
- 2002-03-19 WO PCT/US2002/008279 patent/WO2002090526A2/fr not_active Ceased
- 2002-03-19 AU AU2002324424A patent/AU2002324424A1/en not_active Abandoned
- 2002-03-19 EP EP02749512A patent/EP1381622A2/fr not_active Withdrawn
- 2002-03-19 AU AU2002320013A patent/AU2002320013A1/en not_active Abandoned
- 2002-03-19 AU AU2002326293A patent/AU2002326293A1/en not_active Abandoned
- 2002-03-19 EP EP02799146A patent/EP1390390A4/fr not_active Withdrawn
- 2002-03-19 EP EP02759068A patent/EP1404702A4/fr not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008276 patent/WO2002076488A1/fr not_active Ceased
- 2002-03-19 EP EP02760994A patent/EP1379132A4/fr not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008278 patent/WO2002102994A2/fr not_active Ceased
- 2002-03-19 CA CA002441397A patent/CA2441397A1/fr not_active Abandoned
- 2002-03-19 AU AU2002354719A patent/AU2002354719A1/en not_active Abandoned
- 2002-03-19 EP EP02782476A patent/EP1414845A4/fr not_active Withdrawn
- 2002-03-19 WO PCT/US2002/009785 patent/WO2002095010A2/fr not_active Ceased
- 2002-03-19 WO PCT/US2002/008123 patent/WO2002102993A2/fr not_active Ceased
- 2002-03-19 CA CA002441416A patent/CA2441416A1/fr not_active Abandoned
- 2002-03-19 WO PCT/US2002/008124 patent/WO2003004622A2/fr not_active Ceased
- 2002-03-19 CA CA002441417A patent/CA2441417A1/fr not_active Abandoned
- 2002-03-19 CA CA002441755A patent/CA2441755A1/fr not_active Abandoned
- 2002-03-19 EP EP02723499A patent/EP1379264A4/fr not_active Withdrawn
- 2002-03-19 AU AU2002363296A patent/AU2002363296A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2441702A1 (fr) | Proteines secretees par l'homme | |
| CA2442797A1 (fr) | Proteines secretees humaines | |
| CA2393616A1 (fr) | Acides nucleiques, proteines et anticorps | |
| US20020015950A1 (en) | Atherosclerosis-associated genes | |
| JP4208951B2 (ja) | 幹細胞増殖因子様ポリペプチドおよびポリヌクレオチドに関する方法および材料 | |
| CA2395885A1 (fr) | Acides nucleiques, proteines et anticorps | |
| EP1355666B1 (fr) | Utilisation de "repulsive guidance molecule" (RGM) et de ses modulateurs | |
| CA2421949A1 (fr) | Noveaux acides nucleiques et polypeptides | |
| CA2291260A1 (fr) | 207 proteines secretees par l'etre humain | |
| CA2332109A1 (fr) | 97 proteines humaines secretees | |
| JP2002501738A (ja) | ６７個のヒト分泌タンパク質 | |
| JP2002502600A (ja) | ヒトセリンプロテアーゼおよびセルピンポリペプチド | |
| JP2001514885A (ja) | ７０個のヒト分泌タンパク質 | |
| JP2001514024A (ja) | ５０個のヒト分泌タンパク質 | |
| JP2003525566A (ja) | １２５個のヒト分泌タンパク質 | |
| EP1572887A2 (fr) | Peptides de regeneration neurale et procedes d'utilisation de ces derniers dans le traitement des lesions cerebrales | |
| AU2002252266A1 (en) | Human serpin polypeptides | |
| JP2003521865A (ja) | １４８個のヒト分泌タンパク質 | |
| WO2004074436A2 (fr) | Procede d'utilisation d'un gpcr pour diagnostiquer et traiter le cancer du colon et du poumon | |
| CN101550185B (zh) | 新的肿瘤相关基因或蛋白及其应用 | |
| JP2002360254A (ja) | 新規膜結合型−分泌型ｍｅｇｆ８遺伝子及びそれにコードされる蛋白質 | |
| JP2004518425A (ja) | 幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関連した方法および物質 | |
| JP2003523733A (ja) | １０個のヒト分泌タンパク質 | |
| EP1683865A2 (fr) | Protéines de mammifères en particulier CD200 | |
| JPWO2001009321A1 (ja) | 新規なｔｓｐ１様蛋白質をコードする遺伝子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |